Selected Publications
2023
I Wiethoff, M Sikking, S Evers, A Gabrio, M Henkens, M Michels, J Verdonschot, S Heymans, M Hiligsmann (2023). Quality of life and societal costs in patients with dilated cardiomyopathy, European Heart Journal-Quality of Care and Clinical Outcomes.
L Koeser, F Rost, A Gabrio, T Booker, D Taylor, P Fonagy, D Goldberg, M Knapp, P McCrone (2023). Cost-effectiveness of long-term psychoanalytic psychotherapy for treatment-resistant depression: RCT evidence from the Tavistock Adult Depression Study (TADS), Journal of Affective Disorders, 335, 313-321.
Gabrio A (2023). A review of heath economic evaluation practice in the Netherlands: are we moving forward ?, Health Economics, Policy and Law, 1-18.
Koeser L, Rost F, Gabrio A, Booker T, Taylor D, Fonagy P, Goldberg David, Knapp Martin, McCrone Paul (2023). Cost-effectiveness of long-term psychoanalytic psychotherapy for treatment resistant depression: RCT evidence from the Tavistock Adult Depression Study (TADS), Journal of Affective Disorders, 335, 313-321.
2022
Lohan M, Brennan-Wilson A, Hunter R, Gabrio A, McDaid L, Young H, French R, Aventin A, Clarke M, McDowell C, Logan D, Toase S, O’Hare L, Bonell C, Gillespie K, Gough A, Lagdon S, Warren E, Buckley K, Lewis R, Adara L, McShane T, Bailey J, White J (2022). Effects of gender-transformative relationships and sexuality education to reduce adolescent pregnancy (The JACK trial): a cluster randomised trial, The Lancet Public Health, 7(7), E626-E637.
Gabrio A, Gunsoy N, Baio G, Martin A, Paly V, Risebrough N, et al. (2022). Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modelling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT trial. International Journal of Chronic Obstructive Pulmonary Disease, 1633-1642.
Gabrio A, Plumpton C, Banerjee S, Leurent B (2022). Linear mixed models to handle missing at random data in trial-based economic evaluations, Health Economics, 31(6), 1276-1287.
Ling X, Gabrio A, Mason AJ, Baio G (2022). A scoping review of item-level missing data in within-trial cost-effectiveness analysis. Value in Health - pre-print version.
2021
Rooijackers TH, Metzelthin SF, van Rossum E, Kempen GIJM, Evers SMAA, Gabrio A, Zijlstra GAR (2021). Economic Evaluation of a Reablement Training Program for Homecare Staff Targeting Sedentary Behavior in Community-Dwelling Older Adults Compared to Usual Care: A Cluster Randomized. Controlled Trial. Clin Interv Aging: 16:2095-2109
Gabrio, A. (2021). A Bayesian framework for patient-level partitioned survival cost-utility analysis. Medical Decision Making: 41(8), 1033-1048.
Gabrio, A., Hunter, R., Mason, J.M., Baio, G. (2021). Joint longitudinal models for dealing with missing at random data in trial-based economic evaluations . Value in Health: 24(5), 699-706.
2020
Clarke, C., Brawley, C., Ingleby, F., Gabrio, A., Dearnaley, D., Matheson, D., Attard, G., Rush, H., Jones, R., Clarke, N., Parmar, M., Sydes, M., Hunter, R., James, N. (2020). Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. Journal of Clinical Oncology: 38(2): 204.
Gabrio, A. 2020. Bayesian Hierarchical Models for the Prediction of Volleyball Results. Journal of Applied Statistics : 1-21, 2020.
Gabrio, A., Daniels, J.M., Baio, G. 2020. A Bayesian Parametric Approach to Handle Missing Longitudinal Outcome Data in Trial-Based Health Economic Evaluations. Journal of the Royal Statistical Society, Series A: 183(2): 607-29.
2019
Gabrio, A; Baio, G; and Manca. Bayesian Statistical Economic Evaluation Methods for Health Technology Assessment. In Oxford Research Encyclopedia of Economics and Finance . Oxford University Press, Oxford, UK, 2019.
Gabrio, A., Mason, J.M., Baio, G. 2019. A Full Bayesian Model to Handle Structural Ones and Missingness in Economic Evaluations from Individual-Level Data . Statistics in Medicine: 38(8): 1399-1420 .
2017
Gabrio, A., Mason, J.M., Baio, G. 2017. Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: a Review with Future Recommendations. PharmacoEconomics-Open 1(2): 79-97